Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease (INFLAMMACOV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04424056
Recruitment Status : Not yet recruiting
First Posted : June 9, 2020
Last Update Posted : June 23, 2020
Sponsor:
Information provided by (Responsible Party):
Assistance Publique Hopitaux De Marseille

Brief Summary:

COVID19-associated disease may have different clinical aspects classified in 3 stages. Some patients initially presenting with a non-hypoxemic viral pneumonia (stage 2a) may evolve toward a more severe stage 2b or 3 (acute respiratory distress syndrome, ARDS) around the 7th or 10th day of evolution, with a severe biological inflammatory syndrome (CRP>200 mg/l), and some times more severe complications such as acute renal insufficiency, consumptive coagulopathy or shock, requiring increasing oxygen therapy, ICU admission, invasive mechanical ventilation and possibly leading to death. This detrimental evolution is due to a host-derived "cytokine storm" with a great excess of circulating inflammatory cytokines. In animal models of ARDS complicating coronavirus or influenza virus infection, the cytokine storm has been linked to hyperactivation of the NLRP3 inflammasome. NLRP3 constitutes an intracellular protein platform which is responsible for caspase1 activation and processing of interleukin (IL)-1beta and IL-18 . IL-1b is a major proinflammatory cytokine which induces IL-6, whereas IL-18 is an inducer of interferon gamma (IFNg) production by Th-1 lymphocytes. A blood IL-1/IL-6 signature can be defined by increased neutrophilia and CRP concentrations, whereas an IL-18/IFNg signature is characterized by severe hyperferritinemia, consumptive coagulopathy and cytopenia. A majority of patients with COVID-19 infections seems to have an IL-1/IL-6 signature, evolving in the more severe forms toward an IL-18/IFNg signature, mimicking cytokine profiles observed in other inflammatory diseases such as Still's disease or hemophagocytic syndromes. In Still's disease, therapeutic inhibition of IL-1 or IL-6 has proven to be very efficient strategies. During hemophagocytic syndromes, inhibition of IFNg is effective in humans notably through blockade of its receptor signalization, using the JAK kinase inhibitor ruxolitinib.

Following this strategy, we propose to use biological drugs currently available for inhibition of IL-1 (anakinra), IL-6 (tocilizumab) or IFNg signaling (ruxolitinib) in the severe forms of COVID19-associated disease. Our hypothesis is that IL-1, IL-6 or JAK kinase inhibition will allow:

  1. to prevent stage 2b worsening and the need to be admitted in ICU, by decreasing oxygen-requirement and systemic inflammation
  2. to improve stage 3 and extremely severe stage 3, allowing invasive mechanical ventilation weaning, improving multi-system organ dysfunction, leading to a faster ICU exit.

We propose an open randomized therapeutic trial (1/1/1) on 216 patients with severe stage 2b and 3 of the disease


Condition or disease Intervention/treatment Phase
Covid19 Drug: Anakinra +/- Ruxolitinib (stages 2b/3) Drug: Anakinra and Ruxolitinib (Advanced stage 3) Drug: Tocilizumab +/- ruxolitinib (stages 2b/3) Drug: Tocilizumab and Ruxolitinib (Advanced stage 3) Other: Standard of care Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 216 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Randomized Therapeutic Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease
Estimated Study Start Date : September 1, 2020
Estimated Primary Completion Date : September 30, 2022
Estimated Study Completion Date : November 1, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Anakinra +/- Ruxolitinib

Anakinra +/- Ruxolitinib

According to clinical stage (gradual strategy):

Stage 2b or 3 : Anakinra +/- ruxolitinib depending of evolution; Advanced stage 3 : Anakinra and Ruxolitinib

Drug: Anakinra +/- Ruxolitinib (stages 2b/3)
administration of Anakinra +/- ruxolitinib, depending of evolution

Drug: Anakinra and Ruxolitinib (Advanced stage 3)
administration of Anakinra and ruxolitinib

Experimental: Tocilizumab +/- Ruxolitinib

Tocilizumab +/- Ruxolitinib

According to clinical stage (gradual strategy):

Stage 2b or 3 : Tocilizumab +/- ruxolitinib depending of evolution; Advanced stage 3: Tocilizumab +ruxolitinib

Drug: Tocilizumab +/- ruxolitinib (stages 2b/3)
administration of Tocilizumab +/- ruxolitinib, depending of evolution

Drug: Tocilizumab and Ruxolitinib (Advanced stage 3)
administration of Tocilizumab and Ruxolitinib

Active Comparator: Standard of care
Treatment with drugs or procedures in routine clinical practice
Other: Standard of care
Treatment with drugs or procedures in routine clinical practice




Primary Outcome Measures :
  1. Ventilation free days at D28 [ Time Frame: 28 days ]
    number of days living without mechanical ventilation at D28



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients older than 18 year up to 75 year-old maximum
  • Eligible for resuscitation care in UCI
  • with proven infection with COVID-19, using at least one positive pharyngeal polymerase chain reaction (PCR) test
  • COVID19 infection pneumonia at

    • Stage 2b: Hypoxemic pneumonia (respiratory rate >30/min, Sat O2<90 mm Hg in ambient air) associated with a marked biological inflammatory syndrome (CRP>150mg/l) - or Stage 3: ARDS defined by a mechanically ventilated patient with a PaO2/FiO2 ratio < 300 for more than 24 hours.
    • or Advanced Stage 3: moderate to severe ARDS (PaO2/FiO2 < 200 to PEEP of at least 8 cmH2O) on invasive mechanical ventilation associated with another organ failure or syndrome among : 1) Shock with norepinephrine dosage > 3 mg/hour, 2) Acute renal oligo-anuric failure or requiring extra-renal lavage, 3) Hepatocellular failure or coagulopathy with factor V < 50%, 4) Myocarditis causing acute heart failure and/or shock. , 5) Hemophagocytic syndrome, 6) Hyperferritinemia > 5000 ng/mL

Exclusion Criteria:

  • Patients younger than 18 or older than 75 year-old,
  • Pregnant or breastfeeding woman
  • Patient for whom measures of therapeutic limitations have been issued (non-admission to intensive care unit)
  • Patients treated with immunosuppressant/immunomodulators (Not only the concomitant administration of the following drugs prohibited in the protocol: other JAK inhibitors, corticosteroids, IL6 inhibitors).
  • Patient already included in another interventional therapeutic trial
  • Use of chronic oral corticosteroids > 10 mg prednisone equivalent per day for non-COVID-19 related disease
  • Uncontrolled autoimmune disease
  • Patients with active, suspected or known active systemic bacterial, viral (excluding COVID-19) or fungal infections that are not controlled (not only HIV, HBV or HCV infection and untreated bacterial or mycotic infection)
  • Patients with severe pre-existing uncontrolled organ dysfunction (heart, liver or kidney failure) not related to COVID-19

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04424056


Contacts
Layout table for location contacts
Contact: Gilles Kaplanski, MD gilles.kaplanski@ap-hm.fr

Locations
Layout table for location information
France
Assistance Publique Hôpitaux de Marseille
Marseille, France, 13005
Contact: Gilles Kaplanski       gilles.kaplanski@ap-hm.fr   
Sponsors and Collaborators
Assistance Publique Hopitaux De Marseille
Layout table for additonal information
Responsible Party: Assistance Publique Hopitaux De Marseille
ClinicalTrials.gov Identifier: NCT04424056    
Other Study ID Numbers: 2020-23
First Posted: June 9, 2020    Key Record Dates
Last Update Posted: June 23, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Interleukin 1 Receptor Antagonist Protein
Antirheumatic Agents